Dyax (DYAX) Margin of Safety % (DCF FCF Based) : N/A (As of May. 05, 2024)

View and export this data going back to . Start your Free Trial

What is Dyax Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Dyax's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Dyax's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Dyax's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dyax's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dyax's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Dyax's Margin of Safety % (DCF FCF Based) falls into.

Dyax Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Dyax's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Dyax (DYAX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyax Corp (NAS:DYAX) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.dyax.com

Dyax Corp was incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. It is a biopharmaceutical company focused on Hereditary Angioedema and Other Plasma-Kallikrein-Mediated Disorders and Licensing and Funded Research Portfolio. The Company develops and commercializes treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. It is engaged in identifying and developing treatments for patients who experience PKM angioedema. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. Excess plasma kallikrein activity plays a role in HAE and could potentially play a role in a number of inflammatory diseases, including Crohn's disease, psoriasis, rheumatoid arthritis, and various mast cell disorders. It also develops KALBITOR for the treatment of acute attacks of HAE. KALBITOR is currently distributed through a limited network of wholesale, hospital and specialty pharmacy arrangements. Its portfolio of product candidates being developed by licensees using its phage display technology. For KALBITOR as a treatment for HAE, its competitors include: Manufacturers of corticosteroids. Other competitors for the treatment of HAE are companies that are developing small molecule plasma kallikrein inhibitors. The preclinical study and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR and those of its licensees, are subject to extensive regulation by governmental authorities in the United States and other countries.

Executives

David J Mclachlan	other: Former director	ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Gustav Christensen	officer: CEO and President, other: Former director	DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Todd Bazemore	officer: EVP & Chief Commercial Officer	C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Thomas L Kempner	other: Former director	C/O LOEB PARTNERS CORPORATION, 125 BROAD STREET, 14TH FLOOR, NEW YORK NY 10004
Abbie Celniker	other: Former director	C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142
Marc D Kozin	other: Former director
Andrew D. Ashe	officer: General Counsel & EVP	C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Ron Cohen	other: Former director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Mary Ann Gray	other: Former director	201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
George V Migausky	officer: EVP & Chief Financial Officer	C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paolo Pucci	other: Former director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Burt A Adelman	officer: CMO & EVP, R&D	DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Ivana Magovcevic-liebisch	officer: EVP; Chief Operating Officer	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Susan B Bayh	director	WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Stephen S Galliker	officer: EVP and CFO	300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139